Cornerstone Planning Group’s Fennec Pharmaceuticals FENC Stock Holding History

Cornerstone Planning Group’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-88	Closed	-$908	–	684
2026 Q2	$908	Hold	88	–	–	﹤0.01%	1533
2026 Q1	$592	Hold	88	–	–	﹤0.01%	1598
2025 Q4	$656	Hold	88	–	–	﹤0.01%	1457
2025 Q3	$733	Hold	88	–	–	﹤0.01%	1391
2025 Q2	$719	Hold	88	–	–	﹤0.01%	1192
2025 Q1	$497	Hold	88	–	–	﹤0.01%	1311
2024 Q4	$576	Hold	88	–	–	﹤0.01%	1093
2024 Q3	$422	Buy	+88	New	+$509	﹤0.01%	1122
2024 Q2	–	Sell	-66	Closed	-$610	–	1291
2024 Q1	$610	Buy	+66	New	+$663	﹤0.01%	880

Other funds holding FENC

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

PWMG

Private Wealth Management Group Princeton, New Jersey $445M AUM 13.54% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Cornerstone Planning Group's FENC Position: Q3 2026 in Review

Cornerstone Planning Group sold out of Fennec Pharmaceuticals (FENC) in Q3 2026, closing a stake of 88 shares — an estimated $908 sold.

Cornerstone Planning Group first reported a position in FENC in Q1 2024 and held it in 9 quarters. The position peaked at $908 in Q2 2026. 11 funds tracked by Wall St. Rank hold FENC as of Q3 2026.

Cornerstone Planning Group reported no remaining Fennec Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
Cornerstone Planning Group sold 88 Fennec Pharmaceuticals shares in Q3 2026, an estimated $908.
Cornerstone Planning Group first reported a position in Fennec Pharmaceuticals in Q1 2024 and held it in 9 quarters.
Cornerstone Planning Group's Fennec Pharmaceuticals position peaked at $908 in Q2 2026.
11 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q3 2026.

Based on Cornerstone Planning Group's 13F filing for Q3 2026, filed 16 Oct 2026.